## Package 'UnifiedDoseFinding'

January 20, 2025

Type Package

Title Dose-Finding Methods for Non-Binary Outcomes

Version 0.1.10

Author Chia-Wei Hsu, Haitao Pan, Rongji Mu

Maintainer Chia-Wei Hsu <Chia-Wei.Hsu@stjude.org>

## Description

In many phase I trials, the design goal is to find the dose associated with a certain target toxicity rate. In some trials, the goal can be to find the dose with a certain weighted sum of rates of various toxicity grades. For others, the goal is to find the dose with a certain mean value of a continuous response. This package provides the setup and calculations needed to run a dosefinding trial with non-binary endpoints and performs simulations to assess design's operating characteristics under various scenarios. Three dose finding designs are included in this package: unified phase I design (Ivanova et al. (2009) <doi:10.1111/j.1541-0420.2008.01045.x>), Quasi-CRM/Robust-Quasi-CRM (Yuan et al. (2007) <doi:10.1111/j.1541-0420.2006.00666.x>, Pan et al. (2014) <doi:10.1371/journal.pone.0098147>) and generalized BOIN design (Mu et al. (2018) <doi:10.1111/rssc.12263>). The toxicity endpoints can be handled with these functions including equivalent toxicity score (ETS), total toxicity burden (TTB), general continuous toxicity endpoints, with incorporating ordinal grade toxicity information into dose-finding procedure. These functions allow customization of design characteristics to vary sample size, cohort sizes, target dose-limiting toxicity (DLT) rates, discrete or continuous toxicity score, and incorporate safety and/or stopping rules.

#### License GPL-2

Encoding UTF-8

NeedsCompilation no

**Repository** CRAN

Date/Publication 2022-10-15 22:52:37 UTC

## Contents

get_oc_gBOIN_continu	ous																		2
get_oc_gBOIN_TB													•						3
get_oc_Ivanova_binary				•								•	•	•	•			•	5

get_oc_Ivanova_continuous	7
get_oc_QuasiBOIN	8
get_oc_RQ_CRM	0
next_gBOIN_continuous	2
next_gBOIN_TB 1	3
next_Ivanova_binary	.4
next_Ivanova_continuous	5
next_QuasiBOIN	6
next_RQ_CRM	7
select_mtd_gBOIN_continuous	9
select_mtd_gBOIN_TB	20
select_mtd_Ivanova_binary	!1
select_mtd_Ivanova_continuous	2
select_mtd_QuasiBOIN	23
select_mtd_RQ_CRM	!4
2	26

## get\_oc\_gBOIN\_continuous

*Generate operating characteristics for finding the maximum tolerated dose (MTD) using gBOIN design* 

## Description

Index

Obtain the operating characteristics of the general Bayesian optimal interval (gBOIN) design (Mu et al. 2017) for maximum tolerated dose (MTD)-based dosing-finding trials under the continuous measure

## Usage

## Arguments

target	the continuous target score
c_true	the true mean value of the continuous measure
ncohort	the number of cohorts
cohortsize	the cohort size
n.earlystop	the early stopping parameter. The default value is $n.earlystop = 100$
ntrial	the number of simulated trials
mu_1	the lower bound. The default value is $mu_1 = 0.6 * target$

mu_2	the upper bound. The default value is $mu_2 = 1.4 * target$
startdose	the starting dose level. The default value is startdose = $1$
seed	the seed. The default value is seed $= 100$

#### Value

get\_oc\_gBOIN\_continuous() returns the operating characteristics of generalized Bayesian optimal interval design (gBOIN) as a list object, including: (1) selection percentage of each dose, (2) the average number of patients treated at each dose

## Author(s)

Chia-Wei Hsu, Haitao Pan, Rongji Mu

## References

Mu, Rongji, Ying Yuan, Jin Xu, Sumithra J. Mandrekar, and Jun Yin. "gBOIN: a unified modelassisted phase I trial design accounting for toxicity grades, and binary or continuous end points." Journal of the Royal Statistical Society. Series C: Applied Statistics 68, no. 2 (2019): 289-308.

## Examples

<pre>get_oc_gBOIN_TB</pre>	Generate operating characteristics for finding the maximum tolerated
	dose (MTD) defined by Toxicity Burden (TB) Score using gBOIN de-
	sign

## Description

Obtain the operating characteristics of the generalized Bayesian optimal interval (gBOIN) design (Mu et al. 2017) for maximum tolerated dose (MTD) (defined by the toxicity burden (BT) score proposed by Bekele et al. (2004))-based dosing-finding trials using. The algorithm of this function is exactly same to the get\_oc\_gBOIN\_Continuous() just the input parameter is used by the TB score

## Usage

## Arguments

target	the target TB score
pmat	pmat is a list. Each element is a matrix, representing the probability of different toxicity type and scale under different dose levels.
weight	the severity weight
ncohort	the number of cohort
cohortsize	the cohort size
n.earlystop	the early stopping parameter. The default value is $n.earlystop = 100$
ntrial	the number of simulated trial
mu_1	the lower bound. The default value is $p.saf = 0.6 * target$
mu_2	the upper bound. The default value is $mu_2 = 1.4 * target$
startdose	the starting dose level. The default value is startdose = $1$
seed	the seed. The default value is seed = $100$

## Value

get\_oc\_gBOIN\_TB() returns the operating characteristics of generalized Bayesian optimal interval design as a list object, including: (1) selection percentage of each dose, (2) the average number of patients treated at each dose

## Author(s)

Chia-Wei Hsu, Haitao Pan, Rongji Mu

## References

Bekele, B. Nebiyou, and Peter F. Thall. "Dose-finding based on multiple toxicities in a soft tissue sarcoma trial." Journal of the American Statistical Association 99, no. 465 (2004): 26-35.

Rongji Mu, Ying Yuan, Jin Xu, Sumithra J. Mandrekar, Jun Yin: gBOIN: a unified model-assisted phase I trial design accounting for toxicity grades, and binary or continuous end points. Royal Statistical Society 2019

c(0.5,0,0.5,0,0))pmat[[2]] <- rbind(c(0.5,0,0.5,0,0),</pre> c(1,rep(0,4)), c(0.5,0.5,0,0,0), c(0.5,0.5,rep(0,3)), c(0.46,0,0.54,rep(0,2))) pmat[[3]] <- rbind(c(0.5,0,0.5,0,0),</pre> c(0.4,0.6,0,0,0), c(0.25,0.75,0,0,0), c(0.5,0.5,0,0,0), c(1,0,0,0,0)) pmat[[4]] <- rbind(c(0.5,0,0.5,0,0),</pre> c(0.4,0.6,0,0,0), c(0.25,0.75,0,0,0), c(0.5,0.5,0,0,0), c(0.5,0,0.5,0,0)) pmat[[5]] <- rbind(c(0.5,0,0.5,0,0),</pre> c(0,1,0,0,0), c(0.25,0.75,0,0,0), c(0.5,0.5,0,0,0), c(0.5,0,0.5,0,0)) pmat[[6]] <- rbind(c(0,0.5,0.5,0,0),</pre> c(0,1,0,0,0), c(0,1,0,0,0), c(0.5,0.5,0,0,0), c(0.5,0,0.5,0,0)) pmat[[7]] <- rbind(c(0,0.5,0.5,0,0),</pre> c(0,1,0,0,0), c(0,1,0,0,0), c(0,0.5,0.5,0,0), c(0.5,0,0.5,0,0)) pmat[[8]] <- rbind(c(0,0.5,0.5,0,0),</pre> c(0,1,0,0,0), c(0,0,1,0,0), c(0,0.5,0.5,0,0), c(0.5,0,0.5,0,0)) pmat[[9]] <- rbind(c(0,0,1,0,0),</pre> c(0,1,0,0,0), c(0,0,1,0,0), c(0,0,1,0,0), c(0,0,1,0,0)) pmat[[10]] <- rbind(c(0,0,1,0,0),</pre> c(0,1,0,0,0), c(1/3,0,0,2/3,0), c(0,0,1,0,0), c(0,0,1,0,0)) get\_oc\_gBOIN\_TB(target = target, pmat = pmat, weight = weight, ncohort = ncohort, cohortsize = cohortsize, ntrial = ntrial)

get\_oc\_Ivanova\_binary Generate operating characteristics for finding the maximum tolerated dose (MTD) of binary endpoint using design by Ivanova et al (2009)

## Description

Obtain the operating characteristics of the dose-finding design of binary endpoint by Ivanova et al (2009)

## Usage

## Arguments

target	the target toxicity rate
eps	the decision criterion. The default value is $eps = 1$
truetox	a vector containing the true toxicity probabilities of the investigational dose lev- els
ncohort	the number of cohorts
cohortsize	the cohort size
n.earlystop	the early stopping parameter. The default value is $n.earlystop = 100$
ntrial	the number of trials
startdose	the starting dose level. The default value is startdose = $1$
seed	the seed. The default value is seed = $100$

#### Value

get\_oc\_Ivanova\_binary() returns the operating characteristics of Ivanova design as a list object, including: (1) selection percentage at each dose level (2) patients treated at each dose level

## Author(s)

Chia-Wei Hsu, Haitao Pan, Rongji Mu

## References

Ivanova, Anastasia, and Se Hee Kim. "Dose finding for continuous and ordinal outcomes with a monotone objective function: a unified approach." Biometrics 65, no. 1 (2009): 307-315.

```
get_oc_Ivanova_continuous
```

Generate operating characteristics for finding the maximum tolerated dose (MTD) of continuous endpoint using design by Ivanova et al (2009)

## Description

Obtain the operating characteristics of the dose-finding design of continuous endpoint by Ivanova et al (2009)

## Usage

## Arguments

target	the continuous target score
eps	the decision criterion. The default value is $eps = 1$
ptox	the true mean value of the continuous measure
ncohort	the number of cohorts
cohortsize	the cohort size
n.earlystop	the early stopping parameter. The default value is $n.earlystop = 100$
ntrial	the number of simulated trials
startdose	the starting dose level. The default value is startdose = $1$
seed	the seed. The default value is seed = $100$

## Value

get\_oc\_Ivanova\_continuous() returns the operating characteristics of Ivanova design as a list object, including: (1) selection percentage at each dose level (2) patients treated at each dose level

## Author(s)

Chia-Wei Hsu, Fang Wang, Haitao Pan, Rongji Mu

## References

Ivanova, Anastasia, and Se Hee Kim. "Dose finding for continuous and ordinal outcomes with a monotone objective function: a unified approach." Biometrics 65, no. 1 (2009): 307-315.

## Examples

get_oc_QuasiBOIN	Generate operating characteristics for finding the maximum tolerated
	dose (MTD) defined by Equivalent Score (ET) using Quasi-CRM de-
	sign using gBOIN

## Description

Obtain the operating characteristics of Quasi-CRM design (Yuan et al. 2007) and Robust-Quasi-CRM design (Pan et al. 2014) for finding the maximum tolerated dose (MTD) using Equivalent Score (ET) derived from toxicity grade information using the gBOIN design (Mu et al. 2017)

## Usage

## Arguments

target	the target DLT rate
p.true	the true toxicity probability at each dose level
score	the default value is score = seq $(0, 1.5, by = 0.5) / 1.5$
ncohort	the number of cohorts
cohortsize	the cohort size
n.earlystop	the early stopping parameter. The default value is $n.earlystop = 100$
startdose	the starting dose level. The default value is startdose = $1$

p.saf	lower bound. The default value is $p.saf = 0.6 * target$
p.tox	upper bound. The default value is $p.tox = 1.4 * target$
cutoff.eli	the cutoff to eliminate an overly toxic dose for safety. The default value is $cutoff.eli = 0.95$
extrasafe	extrasafe set extrasafe = TRUE to impose a more stringent stopping rule. The default value is extrasafe = FALSE
offset	when extrasafe = TRUE will have effect. The default value is offset = $0.05$
ntrial	the number of simulated trials
seed	the seed. The default value is seed = $100$

#### Value

get\_oc\_QuasiBOIN() returns the operating characteristics of Bayesian optimal interval design as a list object, including: (1) the target DLT rate, (2) the true DLT rate at different scale for each dose level, (3) number of cohort, (4) cohortsize, (5) starting dose level, (6) lower bound, (7) upper bound, (8) selection percentage of each dose level, (9) the average number of patients treated at each dose, (10) the average number of patients responded to toxicity at each dose level

## Author(s)

Chia-Wei Hsu, Haitao Pan, Rongji Mu

#### References

Yuan, Z., R. Chappell, and H. Bailey. "The continual reassessment method for multiple toxicity grades: a Bayesian quasi-likelihood approach." Biometrics 63, no. 1 (2007): 173-179.

Pan, Haitao, Cailin Zhu, Feng Zhang, Ying Yuan, Shemin Zhang, Wenhong Zhang, Chanjuan Li, Ling Wang, and Jielai Xia. "The continual reassessment method for multiple toxicity grades: a Bayesian model selection approach." PloS one 9, no. 5 (2014): e98147.

Mu, Rongji, Ying Yuan, Jin Xu, Sumithra J. Mandrekar, and Jun Yin. "gBOIN: a unified modelassisted phase I trial design accounting for toxicity grades, and binary or continuous end points." Journal of the Royal Statistical Society. Series C: Applied Statistics 68, no. 2 (2019): 289-308.

get\_oc\_RQ\_CRM

Generate operating characteristics for finding the maximum tolerated dose (MTD) defined by Equivalent Score (ET) using Quasi-CRM design

## Description

Obtain the operating characteristics of Quasi-CRM design (Yuan et al. 2007) and Robust-Quasi-CRM design (Pan et al. 2014) for finding the maximum tolerated dose (MTD) using Equivalent Score (ET) derived from toxicity grade information

## Usage

## Arguments

ptox	true toxicity probability at each dose level
skeletons	a matrix to provide multiple skeletons with each row presenting a skeleton. If just one row, the function implements the Quasi-CRM design; if >=2 rows, the function implements the Robust-Quasi-CRM designn
target	the target toxicity score
score	the vector weight for ordinal toxicity levels
cohortsize	the cohort size
ncohort	the number of cohort
n.earlystop	the early stopping parameter. The default value is $n.earlystop = 100$
start.dose	the starting dose level. The default value is start.dose = $1$
mselection	mselection = 1 (or 0) indicate to use Bayesian model selection (or mode averag- ing) to make inference across multiple skeletons. The default value is mselection = 1. It only applies to the Robust-Quasi-CRM design
cutoff.eli	the cutoff to eliminate an overly toxic dose for safety. The default value is $cutoff.eli = 0.90$
ntrial	the number of simulated trials. The default value is $ntrial = 10$
seed	the seed. The default value is seed = $100$

## Value

get\_oc\_RQ\_CRM() returns the operating characteristics of (Robust)-Quasi-CRM design as a list object, including: (1) selection percentage at each dose level (2) patients treated at each dose level

#### Author(s)

Chia-Wei Hsu, Haitao Pan, Rongji Mu

#### References

Yuan, Z., R. Chappell, and H. Bailey. "The continual reassessment method for multiple toxicity grades: a Bayesian quasi-likelihood approach." Biometrics 63, no. 1 (2007): 173-179.

Pan, Haitao, Cailin Zhu, Feng Zhang, Ying Yuan, Shemin Zhang, Wenhong Zhang, Chanjuan Li, Ling Wang, and Jielai Xia. "The continual reassessment method for multiple toxicity grades: a Bayesian model selection approach." PloS one 9, no. 5 (2014): e98147.

## Examples

```
### Scenario 1 in Yuan et al. (2007) and Pan et al. (2014)
target <- 0.47
score <- c(0, 0.5, 1, 1.5)</pre>
cohortsize <- 3
ncohort <- 10
ntrial <- 10
ptox <- matrix(nrow = 4, ncol = 6)</pre>
ptox[1,] <- c(0.83, 0.75, 0.62, 0.51, 0.34, 0.19)
ptox[2,] <- c(0.12, 0.15, 0.18, 0.19, 0.16, 0.11)
ptox[3,] <- c(0.04, 0.07, 0.11, 0.14, 0.15, 0.11)
ptox[4,] <- c(0.01, 0.03, 0.09, 0.16, 0.35, 0.59)
### specify one skeleton (Quasi-CRM design)
p1 <- c(0.11, 0.25, 0.40, 0.55, 0.75, 0.85)
get_oc_RQ_CRM(ptox = ptox, skeletons = p1, target = target,
              score = score, cohortsize = cohortsize,
              ncohort = ncohort, ntrial = ntrial)
```

#### 

### specify three skeletons (Quasi-CRM design)
p1 <- c(0.11, 0.25, 0.40, 0.55, 0.75, 0.85)
p2 <- c(0.05, 0.10, 0.15, 0.25, 0.40, 0.65)
p3 <- c(0.20, 0.40, 0.60, 0.75, 0.85, 0.95)
skeletons <- rbind(p1, p2, p3)</pre>

next\_gBOIN\_continuous Determine the dose for the next cohort of new patients for single-agent trials that aim to find a maximum tolerated dose (MTD) using gBOIN design

## Description

Determine the dose for the next cohort of new patients for single-agent trials that aim to find a MTD under continuous measure using gBOIN design (Mu et al., 2017)

## Usage

```
next_gBOIN_continuous(target, n, y, d, mu_1 = 0.6 * target, mu_2 = 1.4 * target)
```

## Arguments

target	the continuous target score
n	the number of patients enrolled at each dose level
У	the toxicity score at each dose level
d	the current dose level
mu_1	the lower bound. The default value is 0.6 * target
mu_2	the upper bound. The default value is 1.4 * target

## Value

next\_gBOIN\_continuous() returns recommended dose level for the next cohort as a numeric value under continuous measure

## Author(s)

Chia-Wei Hsu, Haitao Pan, Rongji Mu

#### References

Mu, Rongji, Ying Yuan, Jin Xu, Sumithra J. Mandrekar, and Jun Yin. "gBOIN: a unified modelassisted phase I trial design accounting for toxicity grades, and binary or continuous end points." Journal of the Royal Statistical Society. Series C: Applied Statistics 68, no. 2 (2019): 289-308.

```
target <- 1.47
n <- c(3, 3, 3, 9, 0, 0)
y <- c(0.1951265, 1.5434317, 2.1967343, 13.9266838, 0, 0)
d <- 4
next_gBOIN_continuous(target = target, n = n, y = y, d = d)</pre>
```

next\_gBOIN\_TB

Determine the dose for the next cohort of new patients for single-agent trials that aim to find a maximum tolerated dose (MTD) defined by Toxicity Burden (TB) Score using gBOIN design

## Description

Determine the dose for the next cohort of new patients for single-agent trials that aim to find the MTD defined by the toxicity burden (BT) score proposed by Bekele et al. (2004) using the generalized Bayesian optimal interval (gBOIN) design (Mu et al. 2017). The algorithm of this function is exactly same to the next\_mtd\_gBOIN\_Continuous() just the input parameter is used by the TB score

## Usage

next\_gBOIN\_TB(target, n, y, d, mu\_1 = 0.6 \* target, mu\_2 = 1.4 \* target)

## Arguments

target	the target TB score
n	the number of patients enrolled at each dose level
У	the toxicity score at each dose level
d	the current dose level
mu_1	the lower bound. The default value is $0.6 *$ target
mu_2	the upper bound. The default value is 1.4 * target

## Value

next\_gBOIN\_TB() returns recommended dose level for the next cohort as a numeric value under ordinal measure

## Author(s)

Chia-Wei Hsu, Haitao Pan, Rongji Mu

## References

B. Nebiyou Bekele & Peter F Thall (2004) Dose-Finding Based on Multiple Toxicities in a Soft Tissue Sarcoma Trial, Journal of the American Statistical Association

Mu, Rongji, Ying Yuan, Jin Xu, Sumithra J. Mandrekar, and Jun Yin. "gBOIN: a unified modelassisted phase I trial design accounting for toxicity grades, and binary or continuous end points." Journal of the Royal Statistical Society. Series C: Applied Statistics 68, no. 2 (2019): 289-308.

```
target <- 3.344
n <- c(3, 9, 6, 0, 0, 0, 0, 0, 0, 0, 0)
y <- c(5.5, 26.95, 25.3, 0, 0, 0, 0, 0, 0, 0)
d <- 2
next_gBOIN_TB(target = target, n = n, y = y, d = d)</pre>
```

next\_Ivanova\_binary Determine the dose for the next cohort of new patients of binary endpoint using design by Ivanova et al (2009)

## Description

Determine the dose for the next cohort of new patients for single-agent trials of binary endpoint that aim to find a MTD using design by Ivanova et al (2009)

## Usage

next\_Ivanova\_binary(target, eps, y, n, d)

#### Arguments

target	the target toxicity rate
eps	the decision criterion
У	the number of toxicity patients at each dose level
n	the number of patients enrolled at each dose level
d	the current dose level

## Value

next\_Ivanova\_binary() returns recommended dose level for the next cohort as a numeric value

## Author(s)

Chia-Wei Hsu, Haitao Pan, Rongji Mu

## References

Ivanova, Anastasia, and Se Hee Kim. "Dose finding for continuous and ordinal outcomes with a monotone objective function: a unified approach." Biometrics 65, no. 1 (2009): 307-315.

14

## next\_Ivanova\_continuous

## Examples

target <- 0.3
eps <- 1
y <- c(0, 4, 0, 0, 0, 0)
n <- c(3, 15, 0, 0, 0, 0)
d <- 2
next\_Ivanova\_binary(target = target, eps = eps, y = y, n = n, d = d)</pre>

next\_Ivanova\_continuous

Determine the dose for the next cohort of new patients using Inanova design

## Description

Determine the dose for the next cohort of new patients for single-agent trials that aim to find a MTD

## Usage

next\_Ivanova\_continuous(target, eps, c\_resp, n, d)

## Arguments

target	the target toxicity score
eps	the decision criterion
c_resp	the list object. Each element contains continuous value for each measurement at the certain dose level
n	the number of patients enrolled at each dose level
d	the current dose level

## Value

next\_Ivanova\_continuous() returns recommended dose level for the next cohort as a numeric
value

## Author(s)

Chia-Wei Hsu, Haitao Pan, Rongji Mu

## References

Ivanova, Anastasia, and Se Hee Kim. "Dose finding for continuous and ordinal outcomes with a monotone objective function: a unified approach." Biometrics 65, no. 1 (2009): 307-315.

next_QuasiBOIN	Determine the dose for the next cohort of new patients based on equiv-
	alent score (ET)-defined target using gBOIN design

## Description

Determine the dose for the next cohort of new patients for single-agent trials that aim to find a MTD defined by the Equivalent Score (ET) in Quasi-CRM design (Yuan et al. 2007) and Robust-Quasi-CRM design (Pan et al. 2014) using the gBOIN design (Mu et al. 2017)

## Usage

## Arguments

target	the target DLT rate
n	the number of patients enrolled at each dose level
У	the toxicity score at each dose level
d	the current dose level
p.saf	the lower bound. The default value is $p.saf = 0.6 * target$
p.tox	the upper bound. The default value is $p.tox = 1.4 * target$
cutoff.eli	the cutoff to eliminate an overly toxic dose for safety. The default value is $cutoff.eli = 0.95$
extrasafe	extrasafe set extrasafe = TRUE to impose a more stringent stopping . The default value is extrasafe = FALSE
n.earlystop	the early stopping parameter. The default value is $n.earlystop = 100$

16

## next\_RQ\_CRM

## Value

next\_QuasiBOIN() returns recommended dose level for the next cohort as a numeric value under quasi-binary measure

## Author(s)

Chia-Wei Hsu, Haitao Pan, Rongji Mu

#### References

Yuan, Z., R. Chappell, and H. Bailey. "The continual reassessment method for multiple toxicity grades: a Bayesian quasi-likelihood approach." Biometrics 63, no. 1 (2007): 173-179.

Pan, Haitao, Cailin Zhu, Feng Zhang, Ying Yuan, Shemin Zhang, Wenhong Zhang, Chanjuan Li, Ling Wang, and Jielai Xia. "The continual reassessment method for multiple toxicity grades: a Bayesian model selection approach." PloS one 9, no. 5 (2014): e98147.

Mu, Rongji, Ying Yuan, Jin Xu, Sumithra J. Mandrekar, and Jun Yin. "gBOIN: a unified modelassisted phase I trial design accounting for toxicity grades, and binary or continuous end points." Journal of the Royal Statistical Society. Series C: Applied Statistics 68, no. 2 (2019): 289-308.

## Examples

target <- 0.47 / 1.5
n <- c(3, 3, 6, 3, 3, 0)
y <- c(0, 0, 1.333333, 0, 1, 0)
d <- 5
next\_QuasiBOIN(target = target, n = n, y = y, d = d)</pre>

next\_RQ\_CRM

Determine the dose for the next cohort of new patients using Quasi-CRM design

## Description

Determine the dose for the next cohort of new patients for single-agent trials that aim to find a MTD defined by the Equivalent Score (ET) using Quasi-CRM design (Yuan et al. 2007) and Robust-Quasi-CRM design (Pan et al. 2014)

## Usage

## Arguments

target	the target toxicity score
n	the number of patients treated at each dose level
У	the toxicity score at each dose level
dose.curr	the current dose level
score	the vector weight for ordinal toxicity levels
skeleton	a matrix to provide multiple skeletons with each row presenting a skeleton
cutoff.eli	the cutoff to eliminate an overly toxic dose for safety. The default value is $cutoff.eli = 0.90$
mselection	mselection = 1 (or 0) indicate to use Bayesian model selection (or mode averaging) to make inference across multiple skeletons. The default value is mselection = $1$

## Value

next\_RQ\_CRM() returns recommended dose level for the next cohort as a numeric value

## Author(s)

Chia-Wei Hsu, Haitao Pan, Rongji Mu

## References

Yuan, Z., R. Chappell, and H. Bailey. "The continual reassessment method for multiple toxicity grades: a Bayesian quasi-likelihood approach." Biometrics 63, no. 1 (2007): 173-179.

Pan, Haitao, Cailin Zhu, Feng Zhang, Ying Yuan, Shemin Zhang, Wenhong Zhang, Chanjuan Li, Ling Wang, and Jielai Xia. "The continual reassessment method for multiple toxicity grades: a Bayesian model selection approach." PloS one 9, no. 5 (2014): e98147.

```
### Implement Robust-Quasi-CRM design (Pan et al. 2014) with pre-specifying 3 skeletons
target <- 0.47
score <- c(0, 0.5, 1, 1.5)
p1 <- c(0.11, 0.25, 0.40, 0.55, 0.75, 0.85)
p2 <- c(0.05, 0.10, 0.15, 0.25, 0.40, 0.65)
p3 <- c(0.20, 0.40, 0.60, 0.75, 0.85, 0.95)
skeletons <- rbind(p1, p2, p3)
n <- c(3, 3, 3, 9, 3, 0)
y <- c(0, 0, 1, 1.333333, 3, 0)
## Example to get the ET score 1 on dose 3
## Assume three patients their corresponding score on the dose 3 is
## 0.5, 0.5 and 0.5. Then we calculate ET score as this:
## (0.5 + 0.5 + 0.5) / 1.5 = 1
## Example to get the ET score 1.333333 on dose 4
## Assume nine patients their corresponding score on the dose 4 is
```

select\_mtd\_gBOIN\_continuous

Select the maximum tolerated dose (MTD) for single agent trials using gBOIN design

## Description

Select the maximum tolerated dose (MTD) when the trial is completed using gBOIN design (Mu et al. 2017)

#### Usage

select\_mtd\_gBOIN\_continuous(target, npts, ntox)

## Arguments

target	the continuous target score
npts	the number of patients enrolled at each dose level
ntox	the toxicity score at each dose level

## Value

select\_mtd\_gBOIN\_continuous() returns the selected dose

## Author(s)

Chia-Wei Hsu, Haitao Pan, Rongji Mu

## References

Rongji Mu, Ying Yuan, Jin Xu, Sumithra J. Mandrekar, Jun Yin: gBOIN: a unified model-assisted phase I trial design accounting for toxicity grades, and binary or continuous end points. Royal Statistical Society 2019

```
target <- 1.47
n <- c(3, 3, 3, 9, 0, 0)
y <- c(0.1951265, 1.5434317, 2.1967343, 13.9266838, 0, 0)
select_mtd_gBOIN_continuous(target = target, npts = n, ntox = y)</pre>
```

<pre>select_mtd_gBOIN_TB</pre>	Select the maximum tolerated dose (MTD) defined by Toxicity Burden
	(TB) Score for single agent trials using gBOIN design

#### Description

Select the maximum tolerated dose (MTD) defined by the toxicity burden (BT) score proposed by Bekele et al. (2004) when the trial is completed using the generalized Bayesian optimal interval (gBOIN) design (Mu et al. 2017). The algorithm of this function is exactly same to the Select\_mtd\_gBOIN.Continuous() just the input parameter is used by the TB score

## Usage

select\_mtd\_gBOIN\_TB(target, npts, ntox)

## Arguments

target	the continuous target score
npts	the number of patients enrolled at each dose level
ntox	the toxicity score at each dose level

## Value

select\_mtd\_gBOIN\_TB() returns the selected dose

## Author(s)

Chia-Wei Hsu, Haitao Pan, Rongji Mu

## References

B. Nebiyou Bekele & Peter F Thall (2004) Dose-Finding Based on Multiple Toxicities in a Soft Tissue Sarcoma Trial, Journal of the American Statistical Association

Mu, Rongji, Ying Yuan, Jin Xu, Sumithra J. Mandrekar, and Jun Yin. "gBOIN: a unified modelassisted phase I trial design accounting for toxicity grades, and binary or continuous end points." Journal of the Royal Statistical Society. Series C: Applied Statistics 68, no. 2 (2019): 289-308.

## Examples

```
target <- 3.344
n <- c(3, 9, 6, 0, 0, 0, 0, 0, 0, 0)
y <- c(5.5, 26.95, 25.3, 0, 0, 0, 0, 0, 0, 0)
select_mtd_gBOIN_TB(target = target, npts = n, ntox = y)</pre>
```

20

select\_mtd\_Ivanova\_binary

Select the maximum tolerated dose (MTD) of binary endpoint for single agent trials using design by Ivanova et al (2009)

## Description

Select the maximum tolerated dose (MTD) when the trial is completed for binary endpoint using design by Ivanova et al (2009)

## Usage

```
select_mtd_Ivanova_binary(target, y, n)
```

## Arguments

target	the target toxicity rate
У	the number of toxicity patients at each dose level
n	the number of patients enrolled at each dose level

## Value

select\_mtd\_Ivanova\_binary() returns a list object including: (1) dose selected (2) patients treated at each dose level

## Author(s)

Chia-Wei Hsu, Haitao Pan, Rongji Mu

## References

Ivanova, Anastasia, and Se Hee Kim. "Dose finding for continuous and ordinal outcomes with a monotone objective function: a unified approach." Biometrics 65, no. 1 (2009): 307-315.

## Examples

target <- 0.3
y <- c(0, 4, 0, 0, 0, 0)
n <- c(3, 15, 0, 0, 0, 0)
select\_mtd\_Ivanova\_binary(target = target, y = y, n = n)</pre>

#### select\_mtd\_Ivanova\_continuous

Select the maximum tolerated dose (MTD) for single agent trials of continuous endpoint using design by Ivanova et al (2009)

#### Description

Select the maximum tolerated dose (MTD) when the trial is completed for continuous endpoint using design by Ivanova et al (2009)

## Usage

select\_mtd\_Ivanova\_continuous(target, c\_resp, n)

## Arguments

target	the target toxicity score
c_resp	list object. Each element contains continuous value for each measurement
n	the number of patients enrolled at each dose level

## Value

select\_mtd\_Ivanova\_continuous() returns a list object including: (1) dose selected (2) patients treated at each dose level

#### Author(s)

Chia-Wei Hsu, Haitao Pan, Rongji Mu

#### References

Ivanova, Anastasia, and Se Hee Kim. "Dose finding for continuous and ordinal outcomes with a monotone objective function: a unified approach." Biometrics 65, no. 1 (2009): 307-315.

select\_mtd\_QuasiBOIN Select the maximum tolerated dose (MTD)-defined by equivalent score (ET) using gBOIN design

## Description

Select the maximum tolerated dose (MTD) defined by the Equivalent Score (ET) in Quasi-CRM design (Yuan et al. 2007) and Robust-Quasi-CRM design (Pan et al. 2014) when the trial is completed using the gBOIN design (Mu et al. 2017)

## Usage

#### Arguments

target	the target DLT rate
npts	the number of patients enrolled at each dose level
ntox	the toxicity score at each dose level
cutoff.eli	the cutoff to eliminate an overly toxic dose for safety. The default value is $cutoff.eli = 0.95$
extrasafe	extrasafe set extrasafe = TRUE to impose a more stringent stopping rule. The default value is extrasafe = FALSE
offset	when extrasafe = TRUE will have effect. The default value is offset = $0.05$
print	print the additional result or not. The default value is print = FALSE

#### Value

select\_mtd\_QuasiBOIN() returns the selected dose

#### Author(s)

Chia-Wei Hsu, Haitao Pan, Rongji Mu

#### References

Yuan, Z., R. Chappell, and H. Bailey. "The continual reassessment method for multiple toxicity grades: a Bayesian quasi-likelihood approach." Biometrics 63, no. 1 (2007): 173-179.

Pan, Haitao, Cailin Zhu, Feng Zhang, Ying Yuan, Shemin Zhang, Wenhong Zhang, Chanjuan Li, Ling Wang, and Jielai Xia. "The continual reassessment method for multiple toxicity grades: a Bayesian model selection approach." PloS one 9, no. 5 (2014): e98147.

Mu, Rongji, Ying Yuan, Jin Xu, Sumithra J. Mandrekar, and Jun Yin. "gBOIN: a unified modelassisted phase I trial design accounting for toxicity grades, and binary or continuous end points." Journal of the Royal Statistical Society. Series C: Applied Statistics 68, no. 2 (2019): 289-308.

```
target <- 0.47 / 1.5
n <- c(3, 3, 6, 9, 9, 0)
y <- c(0, 0, 1.333333, 2.333333, 3.6666667, 0)
select_mtd_QuasiBOIN(target = target, npts = n, ntox = y)</pre>
```

select\_mtd\_RQ\_CRM Select the maximum tolerated dose (MTD) using Quasi-CRM design

## Description

Select the maximum tolerated dose (MTD) defined by the Equivalent Score (ET) when the trial is completed using Quasi-CRM design (Yuan et al. 2007) and Robust-Quasi-CRM design (Pan et al. 2014)

## Usage

```
select_mtd_RQ_CRM(target, n, y, score, skeleton, mselection = 1)
```

## Arguments

target	the target toxicity score
n	the number of patients treated at each dose level
У	the toxicity score at each dose level
score	the vector weight for ordinal toxicity levels
skeleton	a matrix to provide multiple skeletons with each row presenting a skeleton
mselection	mselection = 1 (or 0) indicate to use Bayesian model selection (or mode averag- ing) to make inference across multiple skeletons. The default value is mselection = $1$

#### Value

select\_mtd\_RQ\_CRM() returns a vector to indicate which dose is selected

## Author(s)

Chia-Wei Hsu, Haitao Pan, Rongji Mu

## References

Yuan, Z., R. Chappell, and H. Bailey. "The continual reassessment method for multiple toxicity grades: a Bayesian quasi-likelihood approach." Biometrics 63, no. 1 (2007): 173-179.

Pan, Haitao, Cailin Zhu, Feng Zhang, Ying Yuan, Shemin Zhang, Wenhong Zhang, Chanjuan Li, Ling Wang, and Jielai Xia. "The continual reassessment method for multiple toxicity grades: a Bayesian model selection approach." PloS one 9, no. 5 (2014): e98147.

24

```
target <- 0.47
score <- c(0, 0.5, 1, 1.5)
p1 <- c(0.11, 0.25, 0.40, 0.55, 0.75, 0.85)
p2 <- c(0.05, 0.10, 0.15, 0.25, 0.40, 0.65)
p3 <- c(0.20, 0.40, 0.60, 0.75, 0.85, 0.95)
skeletons <- rbind(p1, p2, p3)</pre>
n <- c(3, 3, 3, 9, 3, 0)
y <- c(0, 0, 1, 1.333333, 3, 0)
## Example to get the ET score 1 on dose 3
## Assume three patients their corresponding score on the dose 3 is
## 0.5, 0.5 and 0.5. Then we calculate ET score as this:
## (0.5 + 0.5 + 0.5) / 1.5 = 1
## Example to get the ET score 1.333333 on dose 4
## Assume nine patients their corresponding score on the dose 4 is
## 0, 0, 0, 0, 0, 0.5, 0.5 and 1. Then we calculate ET score as this:
## (0 + 0 + 0 + 0 + 0 + 0 + 0.5 + 0.5 + 1) / 1.5 = 1.333333
select_mtd_RQ_CRM(target = target, n = n, y = y, score = score,
                  skeleton = skeletons)
```

# Index

get\_oc\_gBOIN\_continuous, 2
get\_oc\_gBOIN\_TB, 3
get\_oc\_Ivanova\_binary, 5
get\_oc\_Ivanova\_continuous, 7
get\_oc\_QuasiBOIN, 8
get\_oc\_RQ\_CRM, 10

next\_gBOIN\_continuous, 12 next\_gBOIN\_TB, 13 next\_Ivanova\_binary, 14 next\_Ivanova\_continuous, 15 next\_QuasiBOIN, 16 next\_RQ\_CRM, 17

select\_mtd\_gBOIN\_continuous, 19
select\_mtd\_gBOIN\_TB, 20
select\_mtd\_Ivanova\_binary, 21
select\_mtd\_Ivanova\_continuous, 22
select\_mtd\_QuasiBOIN, 23
select\_mtd\_RQ\_CRM, 24